AKT1 and cancer: Shikonin also improves taxol chemosensitivity in ER-negative human breast cells, causing cell cycle arrest in the G2/M phase, and inhibits ERK, Akt, and p70S6 kinase activation, all of which are important in cancer treatment resistance [159].